Terms: = Thyroid cancer AND HERPUD1, ENSG00000051108, 9709, Q15011, SUP, Mif1, KIAA0025, HERP
5 results:
1. Outpatient ablation treatment with two doses of 30 mCi of radioactive iodine for non-low-risk papillary thyroid cancer.
Uno A; Takeda H; Mori M; Yamamoto Y; Takenaka Y; Enomoto K; Takeda N
J Med Invest; 2023; 70(1.2):17-21. PubMed ID: 37164716
[TBL] [Abstract] [Full Text] [Related]
2. A user-friendly nomogram for predicting radioiodine refractory differentiated thyroid cancer.
Meng C; Song J; Long W; Mu Z; Sun Y; Liang J; Lin Y
Front Endocrinol (Lausanne); 2023; 14():1109439. PubMed ID: 36843580
[TBL] [Abstract] [Full Text] [Related]
3. Predictive Value of Clinical and Pathological Characteristics for Metastatic Radioactive Iodine-Refractory Differentiated thyroid Carcinoma: A 16-year Retrospective Study.
Chai J; Zhang R; Zheng W; Zhang G; Jia Q; Tan J; Meng Z; Wang R
Front Endocrinol (Lausanne); 2022; 13():930180. PubMed ID: 35846335
[TBL] [Abstract] [Full Text] [Related]
4. Abnormal Brain Glucose Metabolism in Papillary thyroid cancer Patients 4 Weeks After Withdrawal of Levothyroxine: A Cross-Sectional Study Using
Wu SQ; Feng F; Zou RJ; Fu HL; Sun JW; Jia XZ; Yin YF; Wang H
Front Endocrinol (Lausanne); 2021; 12():595933. PubMed ID: 33776909
[TBL] [Abstract] [Full Text] [Related]
5. Quantitative thyroglobulin response to radioactive iodine treatment in predicting radioactive iodine-refractory thyroid cancer with pulmonary metastasis.
Wang C; Zhang X; Li H; Li X; Lin Y
PLoS One; 2017; 12(7):e0179664. PubMed ID: 28704384
[TBL] [Abstract] [Full Text] [Related]
